Bexion Pharmaceuticals, Inc. Announces Publication of Pediatric Phase 1 (KOURAGE) Results
COVINGTON, Ky., Feb. 23, 2023. Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today results from their clinical trial entitled, " An open-label... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 23, 2023 Category: Pharmaceuticals Source Type: clinical trials
Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease
TOKYO, Feb. 22, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical trial evaluating... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
ADHD Medication AZSTARYS Shown Safe and Effective in Long-Term Study
BOSTON, Feb. 22, 2023. Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today publication of the results from a 12-month, open-label,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With Keytruda (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection
CAMBRIDGE, M.A., and RAHWAY, N.J., Feb. 22, 2023– Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
ReSViNet 2023 Data Reinforce AstraZeneca ’s Commitment to Help Prevent Respiratory Syncytial Virus in Infants
Beyfortus continues to demonstrate consistent protection against RSV disease through the RSV season
New Canadian analysis demonstrates Synagis to be highly cost-effective in 29-35 weeks gestational age infants 21 February 2023 --... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 21, 2023 Category: Pharmaceuticals Source Type: clinical trials
